Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.

Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that chief executive officer Martin Lehr will deliver a corporate presentation at Biotech Showcase™ 2020, being held January 13-15, 2020, at the Hilton San Francisco Union Square in San Francisco.